Walleye Capital’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,600
Closed -$128K 4638
2025
Q4
$128K Buy
+1,600
New +$108K ﹤0.01% 3760
2025
Q2
Sell
-8,300
Closed -$527K 4700
2025
Q1
$527K Sell
8,300
-5,900
-42% -$401K ﹤0.01% 2511
2024
Q4
$1.11M Buy
14,200
+600
+4% +$48.2K ﹤0.01% 2291
2024
Q3
$1.09M Buy
13,600
+13,200
+3,300% +$1.07M ﹤0.01% 2568
2024
Q2
$33.1K Buy
+400
New +$35.2K ﹤0.01% 5031
2019
Q2
Sell
-2,000
Closed -$175K 1852
2019
Q1
$175K Buy
+2,000
New +$182K 0.03% 822

Other funds holding HAE

Walleye Capital's HAE Position: Q1 2026 in Review

Walleye Capital increased its Haemonetics (HAE) stake by 11% in Q1 2026, buying an estimated $418K and bringing the position to 66,359 shares worth $3.74M. The position accounts for 0.02% of the portfolio, ranked #994.

Walleye Capital first reported a position in HAE in Q1 2019 and has held it in 13 quarters since. The position peaked at $14.7M in Q2 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Walleye Capital held 66,359 shares of Haemonetics worth $3.74M as of Q1 2026.
  • Walleye Capital bought 6,411 Haemonetics shares in Q1 2026, an estimated $418K.
  • Haemonetics made up 0.02% of Walleye Capital's portfolio in Q1 2026, its #994 holding.
  • Walleye Capital first reported a position in Haemonetics in Q1 2019 and has held it in 13 quarters since.
  • Walleye Capital's Haemonetics position peaked at $14.7M in Q2 2025.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.